Division of Reproductive Endocrinology and Infertility, University of Pennsylvania, Philadelphia, PA 19104, USA.
Hum Reprod. 2012 Sep;27(9):2690-7. doi: 10.1093/humrep/des216. Epub 2012 Jun 29.
Although close observation of serum estradiol (E2) levels remains a mainstay of assessing clinical response to controlled ovarian stimulation, the prognostic value of any change in E2 levels after administration of hCG remains unclear. The objective of this study is to evaluate the relationship between serum E2 response after hCG administration and the clinical pregnancy and live birth rates in fresh IVF cycles.
We conducted a retrospective cohort study of women aged 21-45 years undergoing their first IVF cycle from 1999 to 2008 at a single practice. We compared the post-hCG serum E2 level with values on the day of hCG trigger. IVF cycles were stratified by post-hCG E2 response and appropriate parametric and non-parametric statistics were performed. Clinical intrauterine pregnancy and live births were the primary outcomes of interest. Multivariable logistic regression models were created to identify predictive factors associated with outcomes while adjusting for potential confounders.
Among the 1712 IVF cycles, 1065 exhibited a >10% increase (Group A), 525 had a plateau (± 10%, Group B) and 122 showed a >10% decrease (Group C) in post-hCG E2 levels. While the E2 levels on the day of hCG were similar across groups, Group C had more patients with diminished ovarian reserve, required higher gonadotrophin doses and had the lowest implantation rates. After adjusting for age, total gonadotrophin dose, infertility diagnosis, number of oocytes and number of transferred embryos, the associations between post-hCG E2 decline (Group C) and clinical pregnancy [adjusted odds ratio (aOR): 0.53; 95% confidence interval (CI): 0.33-0.84, P= 0.007] and live birth (aOR: 0.40; 95% CI: 0.22-0.71, P= 0.002) were significant. We also found significant associations between E2 plateau (Group B) and clinical pregnancy (aOR: 0.73; 95% CI: 0.57-0.94, P= 0.013) and live birth (aOR: 0.74; 95% CI: 0.56-0.97, P= 0.032) when adjusting for the same factors.
In our study, >10% decrease in E2 levels after hCG administration was associated with 40-50% reduction in clinical pregnancy and live birth rates. Similarly, post-hCG E2 plateau (± 10%) lowered the clinical pregnancy and live birth rates by >25%. Our study suggests that the change in the post-hCG E2 level is another parameter that can be used by clinicians to counsel patients regarding their likelihood of success with assisted reproductive technologies prior to oocyte retrieval.
虽然监测血清雌二醇(E2)水平仍然是评估控制性卵巢刺激反应的主要方法,但 hCG 给药后 E2 水平变化的预后价值仍不清楚。本研究旨在评估 hCG 给药后血清 E2 反应与新鲜 IVF 周期中临床妊娠和活产率之间的关系。
我们对 1999 年至 2008 年在一家诊所进行首次 IVF 周期的 21-45 岁女性进行了回顾性队列研究。我们比较了 hCG 触发日的血清 E2 水平与 hCG 后 E2 水平。根据 hCG 后 E2 反应对 IVF 周期进行分层,并进行适当的参数和非参数统计。临床宫内妊娠和活产是主要关注的结局。创建多变量逻辑回归模型,以确定与结局相关的预测因素,同时调整潜在混杂因素。
在 1712 个 IVF 周期中,1065 个周期 E2 水平增加>10%(A 组),525 个周期 E2 水平持平(±10%,B 组),122 个周期 E2 水平下降>10%(C 组)。虽然 hCG 日的 E2 水平在各组之间相似,但 C 组患者卵巢储备功能下降、需要更高剂量的促性腺激素,且着床率最低。调整年龄、总促性腺激素剂量、不孕诊断、卵子数和移植胚胎数后,hCG 后 E2 下降(C 组)与临床妊娠[调整优势比(aOR):0.53;95%置信区间(CI):0.33-0.84,P=0.007]和活产[aOR:0.40;95%CI:0.22-0.71,P=0.002]之间存在显著关联。我们还发现 E2 水平持平(B 组)与临床妊娠[aOR:0.73;95%CI:0.57-0.94,P=0.013]和活产[aOR:0.74;95%CI:0.56-0.97,P=0.032]之间也存在显著关联,在调整相同因素后。
在我们的研究中,hCG 给药后 E2 水平下降>10%与临床妊娠率和活产率降低 40-50%相关。类似地,hCG 后 E2 水平持平(±10%)使临床妊娠率和活产率降低>25%。我们的研究表明,hCG 后 E2 水平的变化是临床医生在取卵前向患者提供关于辅助生殖技术成功可能性的咨询的另一个参数。